Sandex biosimilar Ziextenzo (pegfilgrastim) gets European Commission approval

recently, SwissPharmaceuticals(http://'s generic unit Sandoz announced that the European Commission (EC) has approved the biosimilar Zixenzo (Pegfilgrastim), for the full adaptation of the allergen brand neulastspecifically: for the treatment of malignant tumors (except chronic myeloid leukemia and bone marrow hyperplasia syndrome) for the treatment of cytotoxic chemotherapy, reducing the duration of neutrophil reduction syndrome and the incidence of febrile neutrophil reductionZiextenzo is Sanders' 5th biosimilar approved in the Eu in the past 18 months and thecompany's(http://the world's second-approved biosimilar to dateSix of the eight biosimilars are already on sale in the European Unionabout ZiextenzoZiextenzo is a biosimilar of Neulasta, an Ampinheavy biologicNeulasta is a "whitening"drug(http://used to increase the number of white blood cells in patients, and its active drug is pegfilgrastim (Peffygsin), a recombinant human granulocytic macrophage set stimulator (G-CSF)Neulasta Neulasta is a long-acting form of Ampin Neupogen (non-gesting), which extends the metabolism of the drug in the body with polyglycol (PEG) modification and works better Neulasta, a super-heavyweight product, (http:// with global sales of $4.56 billion in 2017, 87 percent of which came from the U.S market, which contributed about $600 million outside the U.S 　　Neulasta Patent (http:// expired in the United States in June 2015 and in Europe in August 2017 　　Neulasta is a long-acting form of Amgen Neupogen that extends the metabolism of the drug in the body with polyglycol (PEG) modification, which is more effective 　　Neulasta is a super-heavyweight product with global sales of $4.56 billion in 2017, 87 percent of which came from the U.S market, which contributed about $600 million outside the U.S Neulasta's core patents expired in the U.S market in June 2015 and in Europe in August 2017